pubmed.ncbi.nlm.nih.gov

Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association - PubMed

  • ️Invalid Date

Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association

V D Hope et al. Epidemiol Infect. 2014 Feb.

Abstract

Knowledge of hepatitis B and C prevalence, and numbers infected, are important for planning responses. Published HBsAg and anti-HCV prevalences for the 20 WHO European Region countries outside the EU/EFTA were extracted, to complement published data for the EU/EFTA. The general population prevalence of HBsAg (median 3·8%, mean 5·0%, seven countries) ranged from 1·3% (Ukraine) to 13% (Uzbekistan), and anti-HCV (median 2·3%, mean 3·8%, 10 countries) from 0·5% (Serbia, Tajikistan) to 13% (Uzbekistan). People who inject drugs had the highest prevalence of both infections (HBsAg: median 6·8%, mean 8·2%, 13 countries; anti-HCV: median 46%, mean 46%, 17 countries), and prevalence was also elevated in men who have sex with men and sex workers. Simple estimates indicated 13·3 million (1·8%) adults have HBsAg and 15·0 million (2·0%) HCV RNA in the WHO European Region; prevalences were higher outside the EU/EFTA countries. Efforts to prevent, diagnose, and treat these infections need to be maintained and improved. This article may not be reprinted or reused in any way in order to promote any commercial products or services.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.

Prevalence of antibodies to hepatitis C virus (anti-HCV) and hepatitis B surface antigen (HBsAg) in (a) the general adult population; (b) people who inject drugs (PWID) in the WHO European region, by country. Hatched areas on maps indicate countries outside the WHO European Region.

Similar articles

Cited by

References

    1. WHO. Prevention and control of viral hepatitis infection: frame work for global action 2012. Geneva: WHO, 2012. (www.who.int/csr/disease/hepatitis/GHP_framework.pdf). Accessed 14 December 2012.
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004; 11: 97–107. - PubMed
    1. Goldstein ST, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005; 34: 1329–39. - PubMed
    1. World Health Organization. Hepatitis C – global prevalence (update). Weekly Epidemiological Record 1999; 74: 425–27. - PubMed
    1. WHO Executive Board. Viral hepatitis. Report by the Secretariat. EB126/15. Geneva: WHO; 12 November 2009: http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_15-en.pdf.

Publication types

MeSH terms

Substances